Education & Academic Qualifications
- University of Athens School of Medicine (1987)
- July 1990 – July 1991: Internal Medicine – Polyclinic of Athens
- August 1991 – December 1994: Νuclear Medicine – Nucl. Medicine Department Alexandra Univ. Hospital – Athens
- Nuclear medicine in brain imaging (DATSCAN) – 2005 – Parkinson Institute Milan-Polikliniko Milan
- Training in PET AND PET/CT – 2006 and 2009 – Ludwig Maximilians University in Munich
February 1995 – Ph.D, Topic: Myocardial scintigraphic study with I-123 MIBG for the assessment of cardiotoxicity – neurotoxicity of Doxorubicin.
Fellowship in Societies, Membership in Journal Editorial Committees
Member of Hellenic Society of Nuclear Medicine & Molecular Imaging.
Member of E.A.N.M (European Association of Nuclear Medicine).
Member of ASNC (American Society of Nuclear Cardiology).
Member of SNM (Society of Nuclear Medicine).
Member of Medical Society of Athens.
Member of the Editorial Board of the European Journal of Nuclear Medicine and Molecular Imaging
Member of Editorial Board of “Aktinotechologia” Journal
Member of the editorial board of the Journal Nuclear Medicine, Radiology & Radiation Therapy
February 1995 -April 1995 : Nuclear Medicine Department of Medical Centre of Athens, transferred to Medical Centre of Trikala
May 1995 -February 1996: “Centre of Nuclear Medicine of Pireas”
June 1996- December 1999: Scientific Director of Nuclear Medicine Department in “IASO” Hospital SA
December 1999 -31-5-2006: Director of Nuclear Medicine Department in “IASO” Hospital SA
1/6/2006-today “Hygeia” hospital, Director Nuclear Medicine and PET/CT Department
Private school “Ι.Ι.Ε.Κ. SOTIROPOULOU”
1996-1999 Τ.Ε.Ι Athens, “technology of medical instrumentation» Department
14 February 14 1997 – today (Π.Δ 407/80) Scientific collaborator of University of Crete- Medical School
Courses in Radiology II- 2nd semester of 2000
Courses for trainees in Nuclear Medicine 2001-2002, under the auspices of “Hellenic Association of Nuclear Medicine and Biology”
Clinical & Research Interest
PET-CT and PET-MRI
Clinical significance of a positive antimyosin scanning in patients with dilated cardiomyopathy (Sponsored by CENTOCOR – MALLINCKRODT MEDICAL B.V.)
Participation of PET/CT Department in multicenter trial of F. Hoffman-La Roche Ltd company
Participation of PET/CT Department in multicenter trial of WEBEX TRAINING:Novartis CRAD001N2301 PET Sites
Honors & Awards
Award to the presentation “The contribution of myocardial scintigraphy with antimyosin in the diagnosis of acute myocarditis” at the 20th Panhellenic Medical Congress.
Awards to the presentations at the “EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE CONGRESS 1993″with title:
Doxorubicin-induced cardiac neurotoxicity.Study by I-123-metaiodobenzylguanidineSensitivity of dobutamine-thallium imaging is not reduced by beta-blocker therapy αναφέρονται στα HIGHLIGHTS του συνεδρίου Eur.J.Nucl.Med.(1994) 21:159-169 Vol.21,No 2,February 1994
Award to the presentation at the” EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE CONGRESS 1997” with title: CARDIAC I-123-METAIODOBENZYLGUANIDINE UPTAKE IN PREDICTING EARLY AND LATE MORTALITY IN PATIENTS WITH CONGESTIVE HEART FAILURE HIGHLIGHTS of the congress Eur.J.Nucl.Med.(1997) 24:1527-1540 Vol.24,No 12,December 1997
Award to the presentation at the ”4th International Conference of Nuclear Cardiology”, April 18-21,1999,Athens, Greece with title: THE EFFECTS OF LONG-TERM RIGHT VENTRICULAR APICAL PACING ON CARDIAC SYMPATHETIC INNERVATION : AN 1-123-METAIODOBENZYLGUANIDINE (MIBG) SCINTIGRAPHIC STUDY ¨Best Abstract Award ”
Journal of Nuclear Cardiology Jan/Feb 1999,Vol.6 No.1Part 2:S5.
Award to the presentation at the” EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE CONGRESS 1999” με τίτλο: CARDIAC SYMPATHETIC DENERVATION IN CHRONICALLY PACING PATIENTS. AN I-123-METAIODOBENZYLGUANIDINE (MIBG) SCINTIGRAPHIC STUDY HIGHLIGHTS of the congress Eur.J.Nucl.Med.(2000) 27:99-120 Vol.27,No 1, January 2000
Award to the presentation: THE EFFECTS OF LONG-TERM RIGHT VENTRICULAR APICAL PACING ON CARDIAC SYMPATHETIC INNERVATION : AN 1-123-METAIODOBENZYLGUANIDINE (MIBG) SCINTIGRAPHIC STUDY as the best announcement with basic research theme from the Hellenic Cardiology Society Athens, 3 March 2000.
Award to the presentation “Scintimammography in diagnosis of breast cancer” at the 7th Panhellenic Congress of Mastology 16-19 March Athens Greece.
Award to the presentation PET/CT in the estimation of single lung nodule.The role of late images with18F-FDG at the 3d Panhellenic Congress of Oncology Imaging 13-15 December 2013.
Award to the presentation The contribution of PET/CT in the evaluation of response to immunotherapy with Rituximab-CHOP in primary mediastinal B cell lymphoma. Clinical results. 23th Panhellenic Congress of Hematology 2012.
Award to the presentation The correlation between before and after autologous transplantation with 18F-FDG-PET/CT to patients with Hodgkin Lymphoma using different CUTOFF VALUES of the SUVmax from positive or negative PET/CT examination at the 2th Panhellenic Congress of Oncology 9-11 December
Award to the presentation Imaging after therapy to differential thyroid cancer. Can SPECT/CT make the difference? Congress of Oncology Imaging (12/2015)
Springer: “Imaging in clinical oncology”.V. Prassopoulos: “PET/CT Clinical Implication of the Role of 18FDG-PET/CT in Malignant Lymphomas” (pp 249, part V).
Springer:”PET/CT in Lymphomas: A Case-Based Atlas”, V. Prassopoulos co-editor
FLT PET/CT in a Case of Demyelinating Disease. Clin Nucl Med. 2016 Apr 15. [Epub ahead of print]
Prospective PET image quality gain calculation method by optimizing detector parameters. Nucl Med Commun. 2015 Dec;36(12):1253-63
PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia. 2016 Jan;30(1):238-42.
Association between habitual physical activity and brown adipose tissue activity in individuals undergoing PET-CT scan. Clin Endocrinol (Oxf). 2015 Jan;82(1):147-54.
A review of PET normalization: striving for count rate uniformity. Nucl Med Commun. 2013 Nov;34(11):1033-45.
A rare non-small cell lung cancer (18)F-FDG PET/CT study in a young patient with genetic anomaly living in a highly polluted area. Metastatic lesions not shown by CT. Hell J Nucl Med. 2013 May-Aug;16(2):144-5.
Leydig cell tumour of the ovary localised with positron emission tomography/computed tomography. Gynecol Endocrinol. 2011 Oct;27(10):837-9
The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun. 2011 Feb;32(2):85-90.